IMC Chicago’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.76M Buy
30,400
+16,400
+117% +$2.43M ﹤0.01% 1984
2026
Q1
$1.3M Sell
14,000
-10,800
-44% -$956K ﹤0.01% 3004
2025
Q4
$1.99M Sell
24,800
-1,100
-4% -$92.1K ﹤0.01% 2431
2025
Q3
$2.53M Buy
25,900
+5,100
+25% +$411K ﹤0.01% 2064
2025
Q2
$1.45M Sell
20,800
-7,300
-26% -$416K ﹤0.01% 2230
2025
Q1
$1.4M Sell
28,100
-3,100
-10% -$196K ﹤0.01% 2042
2024
Q4
$2.18M Buy
31,200
+5,000
+19% +$415K ﹤0.01% 1811
2024
Q3
$2.75M Sell
26,200
-8,300
-24% -$971K ﹤0.01% 1481
2024
Q2
$4.91M Buy
34,500
+11,000
+47% +$1.27M ﹤0.01% 1076
2024
Q1
$2.62M Buy
+23,500
New +$2.8M ﹤0.01% 1235

Other funds holding ACLS

IMC Chicago's ACLS Position: Q2 2026 in Review

IMC Chicago sold out of Axcelis (ACLS) in Q2 2026, closing a stake of 6,736 shares — an estimated $999K sold.

IMC Chicago first reported a position in ACLS in Q1 2025 and held it in 2 quarters. The position peaked at $627K in Q1 2026. 441 funds tracked by Wall St. Rank hold ACLS as of Q2 2026.

  • IMC Chicago reported no remaining Axcelis position as of Q2 2026 after selling out during the quarter.
  • IMC Chicago sold 6,736 Axcelis shares in Q2 2026, an estimated $999K.
  • IMC Chicago first reported a position in Axcelis in Q1 2025 and held it in 2 quarters.
  • IMC Chicago's Axcelis position peaked at $627K in Q1 2026.
  • 441 funds tracked by Wall St. Rank held Axcelis as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.